Mayo Clinic, Phenomix Awarded First Patent for Obesity Phenotyping

Mayo Clinic and Phenomix have received their inaugural patent for obesity phenotyping, a groundbreaking development in precision medicine for obesity treatment. The patent, titled “Methods and Materials for Assessing and Treating Obesity,” encompasses identifying obesity phenotypes through analyte signatures and administering tailored interventions, such as medications. Obesity phenotyping classifies obesity types based on specific biological mechanisms, allowing for more targeted weight loss solutions, potentially doubling effectiveness. The technology, pioneered by Mayo Clinic's founders Dr. Andres Acosta and Dr. Michael Camilleri, is licensed exclusively to Phenomix. This patent signifies a significant advancement in personalized obesity medicine, covering various aspects of obesity treatment and analysis.

Medigy Insights

Mayo Clinic and Phenomix Sciences have received their first patent, No. 11,740,247, for their groundbreaking obesity phenotyping technology. This patent covers methods for treating obesity by identifying phenotypes through obesity analyte signatures and providing tailored interventions, such as medications. Obesity phenotyping classifies obesity types based on biological mechanisms, offering personalized weight-loss solutions. Developed by Phenomix's founders at Mayo Clinic, the patent is exclusively licensed to Phenomix for developing, manufacturing, and marketing obesity phenotyping tests. It represents a significant step in personalized obesity medicine, covering various aspects of obesity treatment and analysis.

Continue reading at hitconsultant.net